Backed by Bob Langer, for­mer Har­vard prof sets out to test a new way to de­liv­er I/O drugs — dur­ing surgery

3 years ago
Financing
Startups

Where CAR-Ts were in 2012? For­mer Tmu­ni­ty CEO Oz Azam un­veils not-quite-a-psy­che­delics biotech

3 years ago
R&D

Pfiz­er nabs eq­ui­ty stake in Swiss biotech work­ing on celi­ac ther­a­py; Verona gets more cash af­ter COPD win

3 years ago
News Briefing

Roche cuts PhII eye dis­ease pro­gram, one day af­ter an­oth­er biotech flopped in same in­di­ca­tion

3 years ago
R&D

Hous­ton start­up paus­es en­roll­ment in pe­di­atric can­cer tri­al af­ter pa­tient death

3 years ago
R&D

Tale of two SPACs: One strikes a deal as tur­bu­lent mar­ket forces an­oth­er to dis­solve

3 years ago
Financing
R&D

Up­dat­ed: Not known for gene ther­a­py plays, Eli Lil­ly ac­quires hear­ing loss start­up Ak­ou­os for $487M plus CVR

3 years ago
Deals
Cell/Gene Tx

Ko­re­an buy­er jumps in­to M&A game with $566M bid for Aveo On­col­o­gy

3 years ago
Deals

Ap­n­imed touts PhI­Ib da­ta for lead sleep ap­nea pro­gram, prepar­ing to ad­vance to piv­otal stud­ies

3 years ago
R&D

In­vestors who lost mon­ey from Neil Wood­ford's fund file law­suit against in­vest­ment plat­form

3 years ago
Law

Scoop: With in­vestor in­ter­est dried up in mi­cro­bio­me ther­a­pies, DermBiont piv­ots to oth­er top­i­cals and nears close of ...

3 years ago
Financing
Startups

GSK ex­pands AI part­ner­ship with Tem­pus, fronting $70M for ac­cess to 'mul­ti­modal data'

3 years ago
Deals
AI

Sen­a­tors call on NIH to take ac­tion on slow-to-re­port clin­i­cal tri­al spon­sors

3 years ago
FDA+
Law

Top CDER lead­ers rake Co­vis over the coals on its failed con­fir­ma­to­ry tri­al, neg­a­tive da­ta

3 years ago
FDA+

Adder­all sup­ply woes con­tin­ue as the FDA con­firms short­age of im­me­di­ate re­lease cap­sules

3 years ago
Pharma
Manufacturing

ICER on MS drugs: TG's ubli­tux­imab not cost ef­fec­tive at the same price as Roche's ocre­lizum­ab

3 years ago
Pharma

Pfiz­er pe­ti­tions Supreme Court over an­ti-kick­back case, says pri­or opin­ions could 'cut off char­i­ta­ble or fam­i­ly aid'

3 years ago
Law

Mer­ck part­ner NGM Bio takes stock beat­ing af­ter PhII fail­ure in late-stage eye dis­ease

3 years ago
R&D

FDA de­lays Bio­gen's ALS drug re­view by three months, de­ci­sion to now come next April

3 years ago
FDA+

FDA spurns Min­er­va’s schiz­o­phre­nia drug in RTF, send­ing share price in­to tail­spin

3 years ago
R&D
FDA+

Gilead calls dibs on a PhI bis­pe­cif­ic, hands over $60M to cash-strapped Macro­Gen­ics

3 years ago
Deals

Covid-19 roundup: Mod­er­na rewrites agree­ment with Gavi; Bavar­i­an Nordic touts PhII boost­er re­sults

3 years ago
Coronavirus

Spring­Works’ first aware­ness cam­paign res­onates for pa­tients with rare soft tis­sue tu­mor

3 years ago
Pharma
Marketing

Up­dat­ed: Mile­stone Phar­ma claims PhI­II re­demp­tion for its once-failed heart drug, putting it on a path to the FDA

3 years ago
R&D
First page Previous page 437438439440441442443 Next page Last page
A service from the Financial Times